Search results
Author(s):
Chris Wai Hang Lo
,
Yue Fei
,
Bernard Man Yung Cheung
Added:
3 years ago
Author(s):
Anjali Agarwalla
,
Jadry Gruen
,
Carli Peters
,
et al
Added:
2 years ago
Author(s):
Patrick Campbell
,
Selim Krim
,
Hector Ventura
Added:
3 years ago
Heart failure remains a significant burden to the US healthcare system and contributes greatly to the morbidity and mortality of the population. The impact of an ageing population, improved survival in coronary artery disease (CAD) and adverse life-style choices will ultimately result in an increased burden on an already taxed health care system.
Heart failure affects over 5 million people with…
View more
SGLT2i in HFpEF
Author(s):
Mauro Gori
,
Emilia D’Elia
,
Edoardo Sciatti
,
et al
Added:
1 year ago
Article
Author(s):
Juan Tamargo
Added:
3 years ago
Chronic heart failure (HF) is a complex and progressive clinical syndrome resulting from any abnormality of cardiac structure or function. The American College of Cardiology Foundation/American Heart Association guideline defines HF as ‘a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood’.1 The European Society of…
View more
Author(s):
Maria Stefil
,
Matthew Dixon
,
Jameela Bahar
,
et al
Added:
1 year ago
Neprilysin as a Biomarker
Author(s):
Noemi Pavo
,
Suriya Prausmüller
,
Philipp E Bartko
,
et al
Added:
3 years ago
Article
Author(s):
Bao Tran
,
Gregg C Fonarow
Added:
3 years ago
Heart failure (HF) remains a major public health problem resulting in substantial morbidity, mortality and healthcare expenditures globally. The European Society of Cardiology (ESC) 2012 Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure and the American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) 2013 Guideline for the Management of Heart…
View more
Author(s):
Mary-Tiffany Oduah
,
Varun Sundaram
,
Yogesh Reddy
Added:
1 year ago
Author(s):
Ahmad Masri
Added:
11 months ago
ESC-HFA 23 — We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4 (NCT04219826).
This study assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten (Cytokinetics) in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that…
View more